Sionna Cuts 46% of Workforce, Pivots to SION-451 + SION-2222 Dual Combo After SION-719 Failure
SION has more than doubled off its 52-week low of $4.01.
Summary
Sionna announced a 46% workforce reduction and a strategic pivot to advance SION-451 + SION-2222 into Phase 2a after SION-719 failed its Phase 2a trial. Cash runway extends into H2 2029.
Key Events · Product Development and Regulatory · SION
-
46% Workforce Reduction
Board approved restructuring on September 9, 2026, cutting approximately 46% of workforce to focus resources on SION-451 + SION-2222 dual combination program.
-
$6.4M Restructuring Charges
Estimated charges include $5.3M in severance, $0.7M in contract close-out costs for SION-719 add-on program, and $0.4M in stock-based compensation.
-
Cash Runway Extended to H2 2029
Workforce reduction and discontinuation of SION-719 investment extend operating runway from 2028 into the second half of 2029, with $268.3M in cash at Q2 2026 end.
-
SION-451 + SION-2222 Phase 2a in Q1 2027
AscenSION CF trial will be open-label, 28-day study in adults with F508del homozygous CF, switching from Trikafta to the dual combination.
Analysis · SION · Life Sciences
Sionna is making a decisive pivot after its lead CF drug SION-719 failed its Phase 2a trial in August. The company is cutting nearly half its workforce, terminating its Chief Business Officer, and repricing stock options to retain remaining talent. The strategic bet is on SION-451 + SION-2222, a dual combination that will enter Phase 2a in Q1 2027. The post hoc analysis showing -8.6 mmol/L sweat chloride reduction in a subset of patients gives management confidence the NBD1 mechanism still works, but this is exploratory data from a failed trial. The restructuring extends cash runway into the second half of 2029, buying time for the new program to read out. This is a high-stakes reset: the company is essentially betting its remaining resources on one unproven combination after its lead asset failed.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 35.1% of the 1081 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SION was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.5M. The 52-week trading range was $4.01 to $54.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.